Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EMMA Vienna 2017 | Bone imaging in multiple myeloma

Jens Hillengass • 27 Jan 2017
EMMA Vienna 2017
Multiple Myeloma

Jens Hillengass, MD, University Hospital Heidelberg, Heidelberg, Germany discusses imaging in multiple myeloma (MM). He explores current techniques and weighs up the pros and cons of each, including diffusion-weighted imaging (DWI). Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.

More from Jens Hillengass

Clinical implications of imaging in myeloma 1:08
Clinical implications of imaging in myeloma
Jens Hillengass • 14 Sep 2019
Whole-body low-dose CT in myeloma 2:44
Whole-body low-dose CT in myeloma
Jens Hillengass • 14 Sep 2019
Specialised imaging in multiple myeloma 1:05
Specialised imaging in multiple myeloma
Jens Hillengass • 14 Sep 2019
The exciting field of imaging in multiple myeloma 6:48
The exciting field of imaging in multiple myeloma
Jens Hillengass et al. • 18 Oct 2017

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals